S1 Biopharma, Inc.
S1 Biopharma is a clinical-stage biopharmaceutical company dedicated to developing first-in-class, non-hormonal therapies for sexual dysfunction in women and men. Their mission is to bring innovative treatments to address significant unmet medical needs related to sexual health, focusing on restoring the natural balance of neurotransmitters in the brain to improve sexual desire and function.
Industries
Nr. of Employees
small (1-50)
S1 Biopharma, Inc.
New York, New York, United States, North America
Products
Lorexys (SIP-104)
Oral non-hormonal fixed-dose combination therapy designed to restore balance of key neurotransmitters (dopamine, serotonin, norepinephrine) for the treatment of hypoactive sexual desire disorder in women; completed Phase 2a and positioned for Phase 2b.
Orexa (S1P-205)
Oral therapy candidate developed specifically for hypoactive sexual desire disorder in men; advanced to Phase 2a clinical planning with a double-blind placebo-controlled study design.
Additional pipeline candidates (S1B-3006, S1B-307)
Development-stage drug candidates listed in the company's sexual dysfunction pipeline; limited public detail on mechanisms or clinical stage in provided content.
Lorexys (SIP-104)
Oral non-hormonal fixed-dose combination therapy designed to restore balance of key neurotransmitters (dopamine, serotonin, norepinephrine) for the treatment of hypoactive sexual desire disorder in women; completed Phase 2a and positioned for Phase 2b.
Orexa (S1P-205)
Oral therapy candidate developed specifically for hypoactive sexual desire disorder in men; advanced to Phase 2a clinical planning with a double-blind placebo-controlled study design.
Additional pipeline candidates (S1B-3006, S1B-307)
Development-stage drug candidates listed in the company's sexual dysfunction pipeline; limited public detail on mechanisms or clinical stage in provided content.
Services
Partnerships and licensing for drug commercialization
Structuring and executing out-licensing and commercialization agreements to enable regional market entry and milestone-based collaborations.
Partnerships and licensing for drug commercialization
Structuring and executing out-licensing and commercialization agreements to enable regional market entry and milestone-based collaborations.
Expertise Areas
- Clinical trial management
- CNS drug development
- Fixed-dose combination formulation
- Therapeutics for sexual dysfunction (HSDD, FSD, male HSDD)
Key Technologies
- CNS-targeted pharmacotherapy
- Fixed-dose combination oral formulations
- Adaptive clinical trial designs (crossover, MAD)
- IND and 505(b)(2) regulatory pathways